default author photo

Daniel V. Catenacci

University of Chicago - Pritzker School of Medicine

Chicago, IL 60637

United States

SCHOLARLY PAPERS

2

DOWNLOADS

281

TOTAL CITATIONS

1

Scholarly Papers (2)

1.

Randomised Phase 3 Study of Ivosidenib in IDH1-Mutant Chemotherapy-Refractory Cholangiocarcinoma

Number of pages: 261 Posted: 08 Dec 2019
Memorial Sloan Kettering Cancer Center - Department of Medicine, Hospital Vall d’Hebron, University of Texas at Houston - MD Anderson Cancer Center, University of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center, University of Wisconsin-Madison - Carbone Cancer Center, Hospital Universitario 12 de Octubre - Department of Medical Oncology, Harvard University - Dana-Farber Cancer Institute, University of Chicago - Pritzker School of Medicine, Mayo Clinic Hospital - Phoenix, University College London - UCL Cancer Institute, University of Washington - Department of Medicine, Johns Hopkins University - Sidney Kimmel Comprehensive Cancer Center, Seoul National University - Department of Internal Medicine, Utah Cancer Specialists, Trinity College (Dublin), Harvard University - Department of Medicine, University of Arizona - Department of Medicine, University of Southern California - Norris Comprehensive Cancer Center, Agios Pharmaceuticals, Inc., Agios Pharmaceuticals, Inc., Agios Pharmaceuticals, Inc., Agios Pharmaceuticals, Inc., Agios Pharmaceuticals, Inc., Agios Pharmaceuticals, Inc., The Christie NHS Foundation Trust - Department of Medical Oncology and Harvard University - Cancer Center
Downloads 144 (511,933)

Abstract:

Loading...

Cholangiocarcinoma; IDH1 mutation; Ivosidenib; Phase 3 study

2.

Pemigatinib for Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma

Number of pages: 40 Posted: 02 Dec 2019
Memorial Sloan Kettering Cancer Center - Department of Medicine, University of Michigan at Ann Arbor, University of Paris-Saclay - Gustave Roussy Cancer Center, Providence Cancer Center, University of Verona, University of Kansas - Cancer Center, Baylor University - Charles A. Sammons Cancer Center, Mayo Clinic Hospital - Phoenix, Morristown Memorial Hospital, Johns Hopkins University - Sidney Kimmel Comprehensive Cancer Center, Seoul National University - Department of Internal Medicine, Temple University - Fox Chase Cancer Center, University of Chicago - Pritzker School of Medicine, KU Leuven, Incyte Corporation, Incyte Corporation, Incyte Corporation, Incyte Corporation and Hannover Medical School - Department of Gastroenterology, Hepatology and Endocrinology
Downloads 137 (534,155)
Citation 1

Abstract:

Loading...

FGR2, fusion; rearrangement; pemigatinib; INCB054828; intrahepatic cholangiocarcinoma; cholangiocarcinoma; biliary tract cancer